Crinetics Pharmaceuticals (CRNX) Total Non-Current Liabilities (2017 - 2026)

Crinetics Pharmaceuticals' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $115.8 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 9.65% year-over-year to $115.8 million in Q1 2026; TTM through Mar 2026 was $115.8 million, a 9.65% increase from a year earlier, with the FY2025 full-year figure at $130.9 million, up 20.17% from the prior year.
• Total Non-Current Liabilities declined to $115.8 million in Q1 2026 per CRNX's latest filing, from $130.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $130.9 million in Q4 2025 and bottomed at $96.2 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $109.0 million (2024), against an average of $111.4 million.
• Across the five-year window, Total Non-Current Liabilities grew 20.17% in 2025 and increased 9.65% in 2026, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $96.2 million in 2023, then climbed by 13.21% to $109.0 million in 2024, then climbed by 20.17% to $130.9 million in 2025, then slipped by 11.6% to $115.8 million in 2026.
• Per Business Quant, the three latest CRNX Total Non-Current Liabilities figures stand at $115.8 million (Q1 2026), $130.9 million (Q4 2025), and $121.0 million (Q3 2025).